Prof. Jun Ma 马骏
Oncology
Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public sources. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionCurrent positions
- Academician, Chinese Academy of Sciences (elected 2023)
Checked against a public report (2025-04). Positions change; the hospital's website is the final word.
Clinical focus: Intensity-modulated radiation therapy for nasopharyngeal carcinoma, optimized induction chemotherapy, toxicity-reduction treatment, re-irradiation for recurrent cases, and radiotherapy combined with immunotherapy.
Conditions and procedures: Nasopharyngeal carcinoma, Recurrent nasopharyngeal carcinoma
Compiled from public information; not confirmed with the hospital or the doctor.
Name order: in Chinese the family name comes first (Ma Jun). Papers usually list the name as Jun Ma.
Selected publications
70 first- or senior-author papers on PubMed where the author's own affiliation is this hospital (70 since 2016), counted among the 200 most recent matching papers. Most recent:
- Med, 2026 (senior author): Imaging-detected extranodal extension grading and T-category adjustment to refine the TNM-9 classification for nasopharyngeal carcinoma. PubMed 43008736
- J Clin Oncol, 2026 (senior author): Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline. PubMed 43008245
- Lancet Reg Health West Pac, 2026 (senior author): Epstein-Barr virus based biomarkers and targeted therapies in nasopharyngeal carcinoma: a narrative review. PubMed 42695022
- Med, 2026 (senior author): Patient-reported outcomes from a phase 2 PLATINUM trial of nivolumab combination therapy sparing concurrent cisplatin in nasopharyngeal carcinoma. PubMed 41690301
- JAMA, 2026 (senior author): Toripalimab-Based Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma-Reply. PubMed 41359350
- Front Med, 2025 (senior author): Predictive biomarkers for immunotherapy in nasopharyngeal carcinoma: from tumor microenvironment to macroenvironment. PubMed 41016964
- JAMA, 2025 (senior author): Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial. PubMed 40839372
- Lancet Oncol, 2025 (senior author): Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas. PubMed 40907527
Each paper was checked automatically: the author listed with this name must give this hospital as their affiliation; because this name is common, the affiliation must also name the specialty. See the full PubMed search.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and recommend a treatment plan.
Get a specialist opinion